Wilex AG

Company

    • Company type:
      • Research & Development
    • Year founded:
    • 1997
    • Employees (at the site):
    • 118
    • Turnover range:
    • <5m EUR
    • Products/services:
    • Oncology; Biotechnological therapeutics development; Preclinical/clinical Research; Vaccination and Immunotherapy
      Oncology; Biotechnological therapeutics development; Preclinical/clinical Research; Vaccination and Immunotherapy; biotechnology; pharmacentical development; kidney cancer; breast cancer; antibodies

    • Core competencies:
    • WILEX’s mission is to develop drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours.

      The Company's product candidates are based on antibodies and small molecules. WILEX has an attractive product pipeline which includes both drug and diagnostic candidates: The substances RENCAREX® and REDECTANE® are currently undergoing a Phase III registration trial. MESUPRON® is in a Phase II programme in two indications.
      The MEK-inhibitor WX-554 is in a Phase I study. Four other oncological programmes are currently still in preclinical development.

    • Language skills:
    • English
      French
      German
      Spanish
    • Key Tech / section:
      • Biotechnology: Preclinical development
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72: Scientific research and development
      • 72.1: Research and experimental development on natural sciences and engineering
      • 72.11: Research and experimental development on biotechnology
    • Certification:
    • GLP / GMP

    • Sales markets - target industries:
    • Pharma; Medizin
    • Sales markets - target countries:
      • France
      • Germany
      • Italy
      • Netherlands
      • Russian Federation
      • Spain
      • United States
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Paul Bevan (Mr.)
      - Management

      Dr. Thomas Borcholte (Mr.)
      - Management

      Peter Llewellyn-Davies (Mr.)
      - Management

      Prof. Dr. Olaf G. Wilhelm (Mr.)
      - Management

      Dr. Jan Schmidt-Brand (Mr.)
      - Management